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Abstract
The mechanism of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cancer cells is not fully
understood. Here, we show that the Akt survival pathway plays an important role in TRAIL resistance in human cancer cells.
Specifically, we found that TRAIL treatment activates the Akt survival pathway and that inhibition of this pathway by the
PI3K inhibitor LY294002 or knockdown of Akt sensitizes resistant cancer cells to TRAIL. Since Akt is negatively regulated by
the tumor suppressor PTEN, we examined the TRAIL sensitivity in PTEN knockdown mouse prostate epithelial cells and
found that PTEN
2/2 cells are more resistant than PTEN
+/+ cells while the sensitivity of PTEN
+/2 cells fell in between. Further,
we showed that overexpression of a mutant PTEN confers TRAIL resistance in PTEN
+/+ cells, supporting a role of PTEN in
TRAIL sensitivity. In TRAIL resistant breast T47D cells, overexpression of the mutant PTEN further increased their resistance
to TRAIL. Taken together, our data indicate that inactivation of functional PTEN and the consequent activation of the Akt
pathway prevents TRAIL-induced apoptosis, leading to TRAIL resistance. Therefore, our results suggest that TRAIL resistance
can be overcome by targeting PTEN or the Akt survival pathway in cancer cells.
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Introduction
TRAIL (or Apo2L) is a member of the tumor necrosis factor
superfamily that selectively induces apoptosis in cancer but not
normal cells, making it an attractive agent for cancer therapy.
TRAIL induces apoptosis through activation of its death receptors
DR4 (TRAIL-R2) and/or DR5 (KILLER, TRAIL-R1, TRICK2)
[1,2,3,4]. When TRAIL binds to DR4 and/or DR5 receptors, the
death receptors become trimerized and then recruit the adaptor
protein FADD (Fas-associated protein with death domain) and
procaspase 8 or procaspase 10 to form the DISC, leading to
caspase 8 activation [1,2]. Activated caspase 8 can directly activate
the effector caspases 3, 6 and 7 to trigger apoptosis or indirectly
induces apoptosis through the tBid-induced caspase 9 mediated
mitochondrial apoptosis pathway [2,4].
Although TRAIL is an attractive therapeutic agent many cancer
cells are resistant to this agent [2]. The mechanisms of TRAIL
resistance are not fully understood, but may occur at multiple
levels from its receptors to executor caspases within its signaling
pathway [2,4]. At the receptor level, mutations in DR4 and DR5
have been found in some tumors including breast and lung cancers
[4]. Increased expression of decoy receptors and decreased DR4/
DR5 expression have been correlated with TRAIL resistance,
although other studies indicated that the expression levels of
TRAIL receptors do not correlate with TRAIL sensitivity. At the
death-inducting signaling complex (DISC) level, c-FLIP is believed
to be a major inhibitor for TRAIL signaling [5,6]. A recent study
showed that TRAIL sensitive non-small cell lung cancer (NSCLC)
cells assemble DISC in lipid rafts of the plasma membrane that
leads to caspase 8 activation, whereas non-raft DISC assembly
leads to the recruitment of c-FLIP and RIP and the activation of
the pro-survival signaling pathways such as NF-kB and ERK1/2
pathways [7]. In addition, it has been shown that anti-apoptotic
members of the Bcl-2 family, including Bcl-2 and Mcl-1, are also
involved in TRAIL resistance [8,9]. The activation of other
survival pathways including the Akt and NF-kB pathways leads to
cell survival and chemoresistance [10]. Consistently, it has been
shown that the activation of the Akt pathway is closely associated
with drug resistance including TRAIL resistance [11,12]. Howev-
er, the exact mechanism by which the Akt pathway causes TRAIL
resistance is not fully understood.
The PI3K/Akt signaling pathway is a prototypic survival
pathway that plays a central role in diverse cellular functions,
including proliferation, growth, survival, and metabolism [13].
Upon growth factor stimulation, PI3K is activated to phosphor-
ylate phosphatidylinositol-3, 4-bisphosphate (PIP2), generating
phosphatidylinsitol-3, 4, 5-triphosphate (PIP3). PIP3 binds to Akt,
then translocates to the plasma membrane where Akt is activated
by sequential phosphorylation at T308 and S473 residues.
Phosphorylation at T308 is mediated by PDK-1 (39-phosphoino-
sitide-dependent kinase 1) while phosphorylation at S473 can be
mediated by several kinases including PDK-1 and mTORC2 [13].
Once activated, Akt can phosphorylate many substrates to exert its
functions. The best-characterized substrate of Akt is the serine/
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can directly phosphorylate and activate mTOR and indirectly
activate mTOR by phosphorylating and inactivating tuberous
sclerosis complex 2 (TSC2). Activated mTOR forms a complex
with Raptor to activate ribosomal protein S6 kinases (S6K) and
inhibit 4E-BP, leading to increased protein translation [13]. It is
known that activation of the PI3K/Akt/mTOR pathway can
increase cell survival and apoptosis resistance induced by a
number of agents [12,13]. For example, overexpression of Akt
increases TRAIL resistance [11,14]. On the other hand, the tumor
suppressor gene PTEN (phosphatase and tensin homolog deleted
on chromosome ten) can dephosphorylate PIP3 to function as a
negative regulator of PI3K/Akt/mTOR signaling. PTEN inacti-
vation leads to the activation of the PI3K/Akt/mTOR signaling
pathway. However, the exact mechanism by which the PI3K/
Akt/mTOR pathway confers TRAIL resistance is not fully
understood.
In this study, we demonstrated that increased activation of the
Akt pathway plays an important role in TRAIL resistance.
Specifically, we showed that TRAIL activates the Akt pathway
and that blockade of Akt activation by the PI3K inhibitor
LY294002 or knockdown of Akt expression by siRNA sensitizes
resistant cells to TRAIL. We also found that reintroduction of
wild-type PTEN into PTEN knockout cells sensitizes PTEN
2/2
cells to TRAIL whereas inactivation of PTEN in PTEN
+/+ and
PTEN
+/2 cells leads to TRAIL resistance. These results suggest
that increased activation of the Akt pathway via inactivation of
PTEN plays an important role in TRAIL resistance.
Materials and Methods
Reagents
LY294002 was purchased from Alexis Biochemicals (San Diego,
CA). Recombinant TRAIL was purchased from PeproTech
(Rocky Hill, NJ). Rabbit polyclonal antibodies against phosphor-
ylated Akt (Ser473), phosphorylated mTOR, phosphorylated
p70S6K, phosphorylated eIF4E, PTEN, total Akt, and poly
(ADP-ribose) polymerase (PARP) were purchased from Cell
Signaling Technology (Beverly, MA). Anti-actin antibody was
purchased from Sigma. The adenoviruses expressing wild-type
and dominant negative PTEN, as well as control adenoviruses
expressing galactosidase (Ad-LacZ), were kindly provided by Dr.
Mengjer Lee (University of Louisville).
Cell lines, culture conditions, and treatment
The human breast cancer T47D cells were obtained from
American Type Culture Collection and maintained in DMEM
with 10% fetal bovine serum (FBS). Human ovarian cancer
SKOV3 cells were cultured in RPMI1640 with 10% FBS,
OVCA432 cells were cultured in MCDB105/M199 medium with
10% FBS as described [15]. PTEN-knockout mouse prostate
epithelial cells (PTEN
2/2 and PTEN
+/2) and normal cells
(PTEN
+/+) were obtained from Dr. Young Chen (Wake Forest
University) and maintained in DMEM with 10% FBS, as
described previously [16]. All cell lines were cultured at 37uCi n
a humidified atmosphere consisting of 5% CO2 and 95% air.
siRNA transfection for knockdown of Akt
Signal Silence siRNA for Akt and corresponding control siRNA
were purchased from Cell Signaling. The transfections were
performed as suggested by the manufacturer with slight modifica-
tions, as described previously [17]. Briefly, T47D cells were plated at
6610
5 per well in six-well plates. The next day, cells were
transfected with Akt or non-target control siRNAs using Oligofecta-
mine (Invitrogen). After 24 h, transfected cells were trypsinized and
plated at 6610
5 per well in six-well plates. 48 h later, transfected
cells were left untreated or treated with TRAIL (100 ng/ml) for
24 h and then harvested for assessing the expression of Akt and
cleaved PARP by Western blot analysis. To determine chemosen-
sitivity, cells with or without transfection were placed at 8,000 per
well in 96-well plates and then treated with TRAIL for 24 h, and
cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assays.
MTT assays
MTT assays were described previously [18].
Western blot analysis
The procedures for preparation of whole-cell protein lysates and
Western blot analysis were described previously [18].
Adenoviruse infections
PTEN
+/+, PTEN
+/2 and PTEN
2/2 mouse prostate epithelial
cells and human breast cancer T47D cells were plated in 60 mm
dishes at 8610
5,6 610
5,5 610
5 and 8610
5 cells per dish,
respectively. The next day, cells were washed with normal
medium and infected with adenoviruses expressing wild-type
PTEN, dominant negative PTEN, or LacZ. During infection, cells
were gently shaken every 10 min for 1 h, and then maintained in
adenovirus containing medium at 37uC in a humidified atmo-
sphere containing 5% CO2. 24 h later, infected cells were switched
to normal medium without adenoviruses and then continuously
cultured for another 48 h. At 72 h after infection, cells were
trypsinized and plated in 60 mm dish at 5610
5 cells. The next
day, cells were left untreated or treated with TRAIL (100 ng/ml)
for 48 h. Cells were harvested for Western blot analysis and the
MTT assay, respectively.
Statistical analysis
Statistical analysis was done using Student’s t test. The data
were presented as the mean 6 SD, and P#0.05 was considered
significant.
Results
Characterization of TRAIL sensitivity in a panel of breast
and ovarian cancer cell lines
To understand the mechanisms of TRAIL resistance, we first
investigated TRAIL sensitivity in 14 cancer cell lines including 3
breast and 11 ovarian cancer cell lines. These cell lines were
treated with different doses of TRAIL for 24 h, and cell
proliferation was measured by the MTT assay. Fig. 1 shows that
these cell lines exhibited the differential TRAIL sensitivity; MDA-
231, DOV13, OV433 and OVCA420 cells were sensitive to
TRAIL whereas the rest of lines were resistant to TRAIL except
MCF-7 cells that showed modest resistance. These data show that
many ovarian and breast cancer cell lines are resistant to TRAIL.
The Akt/mTOR pathway is activated in TRAIL resistant cell
lines
Since many breast and ovarian cancer cell lines are resistant to
TRAIL, it is important to understand the underlying mechanism
of TRAIL resistance. It has been reported that TRAIL can
activate several pro-survival pathways, including Akt, NF-kBa n d
ERK pathways [19,20,21,22]. Because activation of these
pathways modulates cell survival and chemoresistance, it is
conceivable that activation of these pathways contributes to
Akt and TRAIL Resistance
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lines T47D, SKOV3, OVCA432 and OV90 with 100 ng/ml
TRAIL for different periods of time and examined the activation
of the Akt, NF-kB and ERK pathways, as well as expression of the
Bcl-2 family proteins. As shown in Fig. 2A–D, the levels of both
phosphorylated Akt and mTOR protein were increased as early as
2 h and lasted up to 6 h after TRAIL treatment, We also showed
that such activation was not due to an increase in the total Akt and
mTOR proteins, which remained constant (Fig. 2A–D). Moreover,
we showed that p70S6K and elF4E, both are downstream targets
of mTOR, are activated (Fig. 2A and D). These data indicate that
TRAIL can activate the Akt/mTOR pathway in TRAIL resistant
cell lines. Importantly, we showed that Akt and mTOR are not
activated in TRAIL sensitive MCF-7 and OVCA420 cells (Fig. 2E
and F). Thus, our results suggest that activation of Akt/mTOR
pathway is a common event in TRAIL resistant cancer cell lines
and that this pathway may be important in TRAIL resistance. In
addition, we found that TRAIL could activate the MEK/ERK
and NF-kB pathways in OV90 cells, but not in other three cell
lines (data not shown). Furthermore, inhibition of the ERK and
NF-kB pathways by their corresponding pharmacological inhibi-
tors did not affect TRAIL sensitivity in OV90 cells (data not
shown), indicating that the activation of these two pathways may
not be important in TRAIL resistance in this cell line.
Figure 1. Effect of TRAIL on cell proliferation. Human breast
cancer cell lines T47D, MDA231, and MCF7 and ovarian cancer cell lines
DOV13, E52, OV90, OV433, OVCA432, RMG-1, TOV-21G, TOV-112D,
CAOV3, OVCA420, and SKOV3 were treated with various doses of TRAIL
for 24 h. Cell proliferation was determined by MTT assays. Cell
proliferation data are expressed as percentage of untreated cells.
Representative of three independent experiments.
doi:10.1371/journal.pone.0010226.g001
Figure 2. Activation of Akt/mTOR pathway by TRAIL in resistant cell lines but not in sensitive cell lines. T47D (A), SKOV3 (B), OVCA432
(C), OV90 (D), MCF7 (E) and OVCA420 (F) cells were treated with 100 ng/ml TRAIL for 0, 2, 4 and 8 h (in T47D cells, 6 h treatment was included), and
total protein was extracted. The levels of total and phosphorylated Akt (p-AKT), and phosphorylated mTOR (p-mTOR) were determined by Western
blot analysis. In T47D (A) and OV90 (D) cells, the levels of phosphorylated p-p70S6K and phosphorylated elF4E (p-elF4E) were also examined. b-actin
was used as a loading control. Of note, there were two bands for Akt (Akt1 and Akt2) in both OVCA432 and OV90 cells while only one band for Akt
was detected in T47D and SKOV3 cells.
doi:10.1371/journal.pone.0010226.g002
Akt and TRAIL Resistance
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10226Inhibition of Akt activation sensitizes resistant cells to
TRAIL
Since the Akt pathway was activated in all resistant cell lines
tested, we asked whether inhibition of Akt activity could increase
their TRAIL sensitivity in resistant cells. To this end, we treated
T47D cells with the PI3K inhibitor LY294002 and examined the
effect of Akt inhibition on TRAIL-induced apoptosis. As shown in
Fig. 3, TRAIL treatment increased Akt phosphorylation in T47D
cells, which was abolished by LY294002, showing that Akt
activation is PI3K dependent. Similarly, we also showed that
activation of Akt is blocked by LY294002 in OVCA432 cells
(Fig. 3C). Importantly, inhibition of Akt phosphorylation by
LY294002 significantly increased TRAIL-induced PARP cleavage
as compared to cells treated with TRAIL, or LY294002 alone
(Fig. 3A and C). Furthermore, we showed that combined
treatment of TRAIL and LY294002 significantly inhibits cell
proliferation as compared to either agent alone (Fig. 3B and D).
These results strongly suggest that the activation of Akt plays an
important role in TRAIL resistance in cancer cells.
Knockdown of Akt sensitizes breast cancer T47D cells to
TRAIL
Although treatment with the PI3K inhibitor LY294002
increased TRAIL-induced apoptosis, the results may not com-
pletely reflect the exclusive role of Akt in TRAIL resistance
because LY294002 may inhibit other kinases. To investigate the
direct role of Akt activation in TRAIL resistance, we used siRNA
to knockdown Akt expression and then determine the effect of Akt
knockdown on TRAIL sensitivity. We transfected T47D cells with
siRNA against Akt (Akt 1, 2 and 3) or control siRNA and showed
that Akt was efficiently knock downed by Akt siRNA in cells with
or without TRAIL treatment, as compared to cells transfected
with control siRNA (Fig. 4B). Importantly, we showed that
knockdown of Akt sensitized TRAIL induced PARP cleavage as
compared to the same cells transfected with control siRNA
(Fig. 4B). Further, knockdown of Akt increased TRAIL-induced
growth inhibition while such changes were minimal in cells
transfected with control siRNA (Fig. 4A). Thus, our results indicate
that while TRAIL can cause apoptosis, it also activates the Akt
survival pathway to counteract TRAIL-induced apoptosis.
Loss of PTEN confers TRAIL resistance
It has been known that PTEN is a negative regulator of Akt and
that increased Akt activity has been associated with inactivation of
PTEN in several cancers. To understand the mechanism of Akt
activation-mediated TRAIL resistance, we treated PTEN
+/+,
PTEN
+/2 and PTEN
2/2 m o u s ep r o s t a t ee p i t h e l i a lc e l l sw i t h
TRAIL for 48 h and measured cell proliferation by MTT assays.
Figure 3. Inhibition of Akt activity sensitizes resistant cancer cells to TRAIL. A and C, effect of the PI3K inhibitor LY294002 on TRAIL-induced
apoptosis. Breast cancer cell T47D (A) and ovarian cancer cell OVCA432 (C) were left untreated or pretreated with 10 mM LY294002 (LY) for 30 min,
and then treated with or without 100 ng/ml TRAIL for 6 h. Total protein was extracted, and cleaved PARP and total and phosphorylated Akt were
determined by Western blotting. B and D, effect of LY294002 on TRAIL-induced growth inhibition. T47D (B) and OVCA432 cells (D) were left untreated
or pretreated with 10 mM LY294002 for 30 min, and then treated with or without 100 ng/ml TRAIL for 24 h. Cell proliferation was determined by MTT
assays and expressed as percentage of untreated cells. Representative of three independent experiments. **, P,0.001, statistical significance; *,
P,0.01, statistical significance.
doi:10.1371/journal.pone.0010226.g003
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PTEN
+/+ cells whereas TRAIL did not affect cell proliferation in
PTEN
2/2 cells, while PTEN
+/2 cells showed about 13% growth
inhibition after TRAIL treatment. Furthermore, we showed that Akt
is activated in PTEN
2/2 cells but not in PTEN
+/+, while minimal
activation in PTEN
+/2 cells. Importantly, TRAIL treatment caused
significant PARP cleavage in PTEN
+/+ cells, moderate cleavage in
PTEN
+/2 cells and complete absence of cleavage in PTEN
2/2 cells
(Fig. 5B). These results suggest that PTEN is required for TRAIL-
induced apoptosis in mouse prostate epithelial cells.
Since PTEN
2/2 cells are resistant to TRAIL, we asked whether
restoration of PTEN expression affects TRAIL sensitivity in
PTEN
2/2 cells. PTEN
2/2 cells were infected with adenoviruses
expressing wild-type PTEN or LacZ. As shown in Fig. 5C, PTEN
expression was restored in cells infected with adenoviruses
expressing PTEN but not in cells infected with adenoviruses
expressing LacZ. Importantly, we were able to show that
restoration of PTEN expression renders PTEN
2/2 cells sensitive
to TRAIL induced apoptosis and growth inhibition whereas such
effects were not observed in cells infected with control viruses
(Fig. 5C). Since PTEN
+/+ cells are sensitive to TRAIL, we asked
whether inhibition of PTEN function affects TRAIL-induced
apoptosis in PTEN
+/+ cells. To this end, we infected PTEN
+/+ and
PTEN
+/2 cells with adenoviruses expressing a dominant negative
form of PTEN or LacZ, and treated infected cells with TRAIL for
48 h. Fig. 5D shows that introduction of dominant negative form
of PTEN increased p-Akt level in PTEN
+/+ cells. Importantly,
introduction of a dominative negative form of PTEN renders
PTEN
+/+ and PTEN
+/2 cells more resistant to TRAIL (Fig. 5D).
Consistent with the role of Akt in inhibiting apoptosis, TRAIL
induced PARP cleavage was decreased dramatically in PTEN
+/+
and PTEN
+/2 cells after they were infected with viruses expressing
a dominant negative form of PTEN. Furthermore, we showed that
TRAIL-induced growth inhibition in PTEN
+/+ cells infected with
Figure 4. Knockdown of Akt sensitizes breast cancer T47D cells to TRAIL. A, effect of Akt knockdown on cell proliferation. T47D cells were
plated at 6610
5 per well in six-well plates. The next day, cells were transfected with Akt or control siRNAs using Oligofectamine. After 2 d, cells were
left untreated or treated with TRAIL (100 ng/ml) for 24 h, and cell proliferation was determined by MTT assays. Cell proliferation data are expressed as
percentage of untreated cells. Representative of three independent experiments. *, P,0.01, statistical significance. B, effect of Akt knockdown on
TRAIL-induced apoptosis. T47D cells were transfected with Akt or control siRNAs and then treated with or without TRAIL (100 ng/ml) for 24 h as
described in (A). Total protein was extracted for assaying total and phosphorylated Akt (p-AKT) and PARP by Western blot analysis. b-actin was used as
a loading control.
doi:10.1371/journal.pone.0010226.g004
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about 5% but about 27% in the same cells infected with control
adenoviruses (Fig. 5D). We also showed that in PTEN
+/2 cells
infected with dominant negative form of PTEN, cell proliferation
was about 102% as compared to the same cells infected with
control viruses in which cell proliferation was about 81% upon
TRAIL treatment (Fig. 5D, upper panel).
The role of PTEN in TRAIL sensitivity in breast cancer
T47D cells
Since breast cancer T47D cells with a wild-type PTEN were
resistant to TRAIL (Fig. 1), we asked whether modulation of
PTEN function would affect TRAIL sensitivity in T47D cells. To
this end, we infected T47D cells with adenoviruses expressing a
dominant negative form of PTEN or control viruses and then
treated infected cells with TRAIL (100 ng/ml) for 48 h, and the
effect of such treatment on TRAIL sensitivity was determined.
Fig. 6 shows that cells infected with adenovirus expressing a
dominant negative form of PTEN express a higher level of p-Akt
while such an increase was not observed in cells infected with
adenoviruses expressing LacZ, which suggests that PTEN function
was inhibited by a dominant negative form of PTEN (Fig. 6B).
Consistent with the role of Akt in inhibiting apoptosis, cleaved
PARP was significantly reduced in cells expressing a dominant
Figure 5. The role of PTEN in TRAIL sensitivity. A, effect of loss of PTEN in TRAIL-induced growth inhibition. Mouse prostate epithelial
cells with wild type PTEN (PTEN
+/+), PTEN knockout (PTEN
+/2) and heterozygous (PTEN
2/2) were plated in 96-well plates, and then treated with
100 ng/ml TRAIL for 48 h. Cells proliferation was determined by MTT assays and expressed as percentage of untreated cells. Representative of three
independent experiments. *, P,0.01, statistical significance. B, effect of PTEN loss on TRAIL-induced apoptosis. PTEN
+/+, PTEN
+/2, and PTEN
2/2 cells
were treated with 100 ng/ml TRAIL for 48 h as described in (A). Total protein was extracted for assaying total and phosphorylated Akt (p-AKT), PTEN
and PARP by Western blot analysis. b-actin was used as a loading control. C, restored PTEN expression sensitizes PTEN
2/2 cells to TRAIL. PTEN
2/2 cells
(5610
5) were infected with adenoviruses expressing wild-type PTEN (Ad-PTEN wt) or expressing LacZ (Ad-lacZ). At 72 h after infection, cells were
trypsinized and plated in 60 mm dish at 5610
5 cells. The next day, cells were left untreated or treated with TRAIL (100 ng/ml) for 48 h. Cells were
harvested for MTT assays (Upper panel) and Western blot analysis was employed for detecting the levels of PARP and PTEN proteins (lower panel),
respectively. Cell proliferation data were expressed as percentage of untreated cells. Representative of three independent experiments. **, P,0.001,
statistical significance. D, inhibition of PTEN function by a dominant negative form of PTEN confers TRAIL resistance. PTEN
+/+ and PTEN
+/2 cells were
infected with adenoviruses expressing a dominant negative form of PTEN for 72 h and then treated with TRAIL (100 ng/ml) for 48 h. Cells were either
used for growth inhibition by MTT assays (upper panel) or harvested for detecting the levels of PARP, PTEN, and total and phosphorylated Akt by
Western blot analysis (lower panel). Cell proliferation data were expressed as percentage of untreated cells. Representative of three independent
experiments. *, P,0.01, statistical significance. **, P,0.001, statistical significance.
doi:10.1371/journal.pone.0010226.g005
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viruses (Fig. 6B). Furthermore, overexpression of a dominant
negative form of PTEN renders T47D cells more resistant to
TRAIL as compared to the same cells infected with viruses
expressing LacZ (Fig. 6). Therefore, these data suggest that
increased Akt activation due to inactivation of PTEN could confer
TRAIL resistance in cancer cells.
Discussion
In this study, we show that TRAIL activates the Akt survival
pathway in TRAIL-resistant cancer cell lines. We also show that
the underlying mechanism may be due to loss of functional PTEN
because PTEN knockout mouse prostate epithelial cells are
resistant to TRAIL while cells with intact PTEN are sensitive to
TRAIL. Restoring PTEN expression rendered PTEN
2/2 cells
sensitive to TRAIL. Further, inactivation of PTEN enhances the
level of TRAIL resistance in T47D cells. These findings suggest
that activation of the Akt survival pathway plays a critical role in
TRAIL resistance and that the Akt pathway is a potential
therapeutic target to enhance TRAIL-based therapy.
The activation of the Akt pathway has been implicated in
protecting cells by many death stimuli, thereby conferring cell
survival [10,13]. Previous studies suggested that overexpression of
Akt and its upstream regulator PI3K increased TRAIL resistance
in breast and ovarian cancer cells [23,24]. However, the
underlying mechanism of its resistance is not fully understood.
In this study, we showed that while TRAIL induces apoptosis in
cancer cells, it also activates several survival pathways, which may
counteract TRAIL-induced apoptosis, leading to resistance. In
many TRAIL resistant breast and ovarian cancer cell lines but not
sensitive cell lines, the Akt pathway was activated (Fig. 2),
suggesting that the activation of the Akt pathway may be a
common event in TRAIL resistant cells. Consistent with this
notion, we found that inhibition of Akt activation by its
pharmacological inhibitor LY294002 or knockdown of its
expression by siRNA sensitizes TRAIL-resistant cells to TRAIL.
Collectively, these data strongly suggest that activation of the Akt
survival pathway plays a critical role in TRAIL resistance in
ovarian and breast cancer cells and imply that inhibition of this
survival pathway might overcome TRAIL resistance.
We also showed that inhibition of PI3K activity blocked Akt
activation in TRAIL resistant cell lines. Since PI3K can serve as
an upstream positive regulator of Akt, these results suggest that
increased Akt activation is at least in part through the increased
activation of PI3K activity. At the downstream level, it is well
known that Akt exerts its biological functions by phosphorylating
its downstream substrates including mTOR. Activation of mTOR
can increase protein translation, resulting in cell survival [13].
Consistent with this, we found that TRAIL treatment can cause
mTOR phosphorylation and subsequent activation. Our data
suggest that TRAIL may activate the PI3K/Akt/mTOR pathway
to counteract TRAIL-induced apoptosis, leading to TRAIL
resistance.
In cancer cells, the Akt survival pathway can be activated by the
several mechanisms including inactivation of its upstream negative
regulator PTEN. By dephosphorylating and conversing PIP3 to
PIP2, PTEN inhibits Akt activation and subsequently sensitizes
cells to death [10,13]. Consistent with the role of the PI3K/Akt
pathway in TRAIL resistance, we found that loss of PTEN in
mouse prostate epithelial cells confers TRAIL resistance whereas
the same cells with intact PTEN are sensitive to TRAIL while
PTEN
+/2 cells show intermediate resistance. These data suggest
that PTEN indeed plays an important role in TRAIL sensitivity.
Furthermore, we showed that reintroduction of a mutant form of
PTEN into TRAIL resistant T47D cells further increases TRAIL
resistance. Collectively, these data indicate that in TRAIL resistant
cells, loss of PTEN contributes to TRAIL resistance. It has been
known that decreased or loss of PTEN expression occurs in at least
50% of breast and ovarian cancers [25]. It is possible that TRAIL
resistant breast and ovarian cancer cells have decreased levels of
PTEN, which need further investigation. Further, a recent study
showed that overexpression of miR-221&222 down regulates
PTEN, leading to increased activation of Akt and subsequent
TRAIL resistance [26]. Additionally, TRAIL resistant leukemia
cells expressed a higher level of phosphorylated inactive form of
PTEN, which resulted in an increase in Akt activation and TRAIL
resistance [27]. In addition to the role of PTEN in regulating Akt
activation, several studies have shown that Akt activation by
TRAIL treatment can be due to the other mechanisms. For
Figure 6. Inhibition of PTEN function renders breast cancer
T47D cells more resistant to TRAIL. A, effect of inhibition of PTEN
function on cell proliferation. T47D cells (8610
5) were infected with
adenovirus expressing a dominant negative form of PTEN or
adenoviruses expressing LacZ for 72 h and then treated with TRAIL
(100 ng/ml) for 48 h. Cell proliferation was determined by MTT assays.
Cell proliferation data are expressed as percentage of untreated cells.
Representative of three independent experiments. *, P,0.01, statistical
significance. B, effect of inhibition of PTEN function on apoptosis. T47D
cells infected with adenoviruses as described in A were treated with
TRAIL (100 ng/ml) for 48 h and then harvested for analyzing the levels
of PARP, PTEN, total and phosphorylated Akt proteins by Western blot
analysis (lower panel). b-actin was used as a loading control.
doi:10.1371/journal.pone.0010226.g006
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activation and TRAIL resistance [28]. Another mechanism
involves DNA-PKcs-mediated Akt activation [29]. Nevertheless,
the mechanisms by which TRAIL activates Akt are still not fully
understood.
Although TRAIL selectively kills cancer cells but not normal
cells, many cancer cells including breast and ovarian cancer cells
are resistant to TRAIL [30,31]. Accumulating evidence indicates
that TRAIL resistance involves many molecules and pathways
including PI3K/Akt pathway [4]. Although previous studies
showed that overexpression or constitutive expression of Akt
confers TRAIL resistance in cancer cells [11,14], this study is
unique because our work indicates that inducible activation of the
Akt/mTOR survival pathway counteracts TRAIL-induced apop-
tosis, leading to TRAIL resistance, as opposed to previous studies
in which overexpression or constitutive activation of Akt caused
TRAIL resistance [11,14]. Our conclusion is based on the fact that
Akt and its downstream target mTOR are activated in all TRAIL
resistant cell lines tested. Further, we were able to increase TRAIL
sensitivity by inhibiting the Akt pathway using its pharmacological
inhibitor LY294002 or siRNA against Akt.
In summary, we demonstrate that TRAIL activates the Akt
survival pathway. We also demonstrate that inhibition of the Akt
survival pathway sensitizes breast and ovarian cancer cells to
TRAIL. More importantly, we demonstrate that loss of PTEN
confers TRAIL resistance in both mouse prostate epithelial and
human breast T47D cells. Therefore, our findings suggest that
targeting the Akt survival pathway could overcome TRAIL
resistance in breast and ovarian cancer cells.
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